A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs MEDI-2228 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms MEDI2228
- Sponsors MedImmune
- 22 Oct 2019 Planned number of patients changed from 136 to 106.
- 18 Sep 2019 Planned number of patients changed from 129 to 136.
- 23 May 2018 Planned End Date changed from 10 Aug 2020 to 23 Apr 2021.